Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults

• Published in: BMC cancer Vol. 9; no. 1; p. 372
• Main Authors: Robe, Pierre A, Martin, Didier H, Nguyen-Khac, Minh T, Artesi, Maria, Deprez, Manuel, Albert, Adelin, Vanbelle, Sophie, Califice, Stephane, Bredel, Markus, Bours, Vincent
• Format: Journal Article Web Resource
• Language: English
• Published: England BioMed Central Ltd 19.10.2009; BioMed Central; BMC
• Subjects: Adult; Brain cancer; Brain research; Chemotherapy; Development and progression; Disease Progression; Dosage and administration; Drug dosages; Drug therapy; Early Termination of Clinical Trials; Female; Genetics & genetic processes; Glioma - drug therapy; Glioma - pathology; Glioma/drug therapy/pathology; Gliomas; Génétique & processus génétiques; Humans; Kinases; Life sciences; Male; Medical statistics; Middle Aged; Neurosurgery; Patients; Prospective Studies; Radiation therapy; Sciences du vivant; Software; Sulfasalazine; Sulfasalazine - administration & dosage; Sulfasalazine - adverse effects; Sulfasalazine/administration & dosage/adverse effects; Surgery; Toxicity; Treatment Failure; Tumors; Belgium; United States; United States > US

Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an excellent safety profile, we initiated a phase 1/2 clinical study of this anti-inflammatory drug for the treatment o...